JAAD International最新文献_第10页

Video synchronous isotretinoin management is associated with lower risk of patient attrition compared to in-person follow-up: A single-center cohort study involving propensity-score matched analysis of patients with acne 视频同步异维A酸管理与面对面随访相比，患者流失风险更低：一项针对痤疮患者进行倾向分数匹配分析的单中心队列研究

JAAD International Pub Date : 2024-10-16 DOI: 10.1016/j.jdin.2024.09.005

Courtney A. Smith MS , Deeti Pithadia MD , Diana Wang MD, PhD , Marcia Hogeling MD , Carol E. Cheng MD

引用次数: 0

COVID-19 infection or vaccination and hidradenitis suppurativa: A systematic review COVID-19 感染或疫苗接种与化脓性扁桃体炎：系统综述

JAAD International Pub Date : 2024-10-11 DOI: 10.1016/j.jdin.2024.09.004

Alim Osman MS , Megan Jayne Ralston MS , Michael Christopher Povelaitis BS , Mariela Mitre MD, PhD

引用次数: 0

Geospatial analysis of dermatologist distribution and access among US seniors 美国老年人皮肤科医生分布和就诊情况的地理空间分析

JAAD International Pub Date : 2024-10-10 DOI: 10.1016/j.jdin.2024.08.023

Shawn Afvari BS , David A. Collet BS , Anjali Goyal BS , Esewi Aifuwa BSE , Avery H. LaChance MD, MPH , Bijan Safai MD, DSc

引用次数: 0

Inverse association between regional solar radiation and hospital discharges due to bullous diseases in Chile: An ecological study 智利地区太阳辐射与牛皮癣出院率之间的反比关系：生态研究

JAAD International Pub Date : 2024-10-10 DOI: 10.1016/j.jdin.2024.09.003

Ignacio Alarcón BSc , Javier Arellano MD, MCE, MSc

引用次数: 0

The safety and tolerability of berdazimer gel 10.3% in Japanese patients with molluscum contagiosum 贝达霉素凝胶 10.3%对日本软疣患者的安全性和耐受性研究

JAAD International Pub Date : 2024-10-05 DOI: 10.1016/j.jdin.2024.09.002

Makoto Kawashima MD, PhD , Yoshiyuki Kaneko BS , Manami Sawasaki BS , Kyohei Masubuchi BS , Hiroyuki Yasukawa BS , Saki Okada BS , Carolyn Enloe MPH , Carri Geer PhD , Martina Cartwright PhD , Tomoko Maeda-Chubachi MD, PhD , Takeshi Tani BS

{"title":"The safety and tolerability of berdazimer gel 10.3% in Japanese patients with molluscum contagiosum","authors":"Makoto Kawashima MD, PhD , Yoshiyuki Kaneko BS , Manami Sawasaki BS , Kyohei Masubuchi BS , Hiroyuki Yasukawa BS , Saki Okada BS , Carolyn Enloe MPH , Carri Geer PhD , Martina Cartwright PhD , Tomoko Maeda-Chubachi MD, PhD , Takeshi Tani BS","doi":"10.1016/j.jdin.2024.09.002","DOIUrl":"10.1016/j.jdin.2024.09.002","url":null,"abstract":"<div><h3>Background</h3><div>Molluscum contagiosum (MC) is a contagious viral skin infection. Berdazimer gel, 10.3% (SB206 12%) is approved in the United States as the first topical, at-home MC prescription medication.</div></div><div><h3>Objective</h3><div>To assess safety and tolerability of SB206 12% in Japanese patients with MC.</div></div><div><h3>Methods</h3><div>SKN15B01 (JRCT2031230123) was a phase 2, multicenter, single-group, open-label study in Japanese patients ≥2 years old with 3-70 baseline MC lesions. Patients with only periocular MC and/or immunosuppression were excluded. SB206 12% was applied once daily to lesions for 12 weeks. Safety endpoints included adverse events and local skin reactions. Exploratory efficacy endpoints included percentage of patients with complete lesion clearance and lesion count percent change from baseline.</div></div><div><h3>Results</h3><div>Twenty patients (12 males, 8 females) with mean (range) age of 5.2 (3-13) years and mean (range) baseline lesion counts of 22.5 (8-44). Complete clearance and percent change from baseline at week 12 were 60% and −89.2%, respectively. The most common treatment-related adverse events were application site-erythema (25%, <em>n</em> = 5), -pain (25%, <em>n</em> = 5), -pruritis (25%, <em>n</em> = 5), and -dermatitis (20%, <em>n</em> = 4), all mild/moderate in severity.</div></div><div><h3>Limitations</h3><div>Single-group study; small sample size.</div></div><div><h3>Conclusion</h3><div>Safety and efficacy of berdazimer gel, 10.3% in Japanese patients were favorable and consistent with previous studies.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 8-16"},"PeriodicalIF":0.0,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142552525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study) 古舍库单抗在欧洲掌跖脓疱病患者中的疗效和安全性：多中心、单臂临床试验（GAP 研究）

JAAD International Pub Date : 2024-10-02 DOI: 10.1016/j.jdin.2024.09.001

Dagmar Wilsmann-Theis MD, PhD , Selina Patt , Andreas Pinter MD, PhD , Sascha Gerdes MD, PhD , Nina Magnolo MD , Robert Németh PhD , Jennifer Schmitz MSc , Cornelia Paul MD , Matthias Augustin MD, PhD , Petra Staubach MD, PhD , Ansgar Weyergraf MD , Ulrike Hüffmeier MD , Kerstin Wolk PhD , Robert Sabat MD, PhD , Rotraut Mößner MD, PhD

{"title":"Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study)","authors":"Dagmar Wilsmann-Theis MD, PhD , Selina Patt , Andreas Pinter MD, PhD , Sascha Gerdes MD, PhD , Nina Magnolo MD , Robert Németh PhD , Jennifer Schmitz MSc , Cornelia Paul MD , Matthias Augustin MD, PhD , Petra Staubach MD, PhD , Ansgar Weyergraf MD , Ulrike Hüffmeier MD , Kerstin Wolk PhD , Robert Sabat MD, PhD , Rotraut Mößner MD, PhD","doi":"10.1016/j.jdin.2024.09.001","DOIUrl":"10.1016/j.jdin.2024.09.001","url":null,"abstract":"<div><h3>Background</h3><div>Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disorder that affects palms and soles. Patients suffer significant pain, itching, and daily activity impairment. Guselkumab, an interleukin-23 inhibitor, has been approved for PPP treatment in Japan. However, there is no effective therapy licensed for PPP in Europe and the USA.</div></div><div><h3>Objective</h3><div>To explore the efficacy and safety of guselkumab in patients with moderate-to-severe PPP in the Caucasian population.</div></div><div><h3>Methods</h3><div>A multicenter, single-arm, phase II study involving 50 patients with moderate-to-severe PPP treated with 100 mg guselkumab subcutaneously for 24 weeks was conducted (GAP). Primary endpoint was the reduction of palmoplantar-pustulosis psoriasis area and severity index (PPPASI) at week 24 compared to baseline. Secondary endpoints included physician-assessed and patient-reported measures. Serum samples were taken for exploratory studies.</div></div><div><h3>Results</h3><div>The primary endpoint was met with a significant median PPPASI reduction by 59.6% at week 24 compared to baseline (<em>P</em> < .001). The proportions of patients achieving PPPASI-50 and PPPASI-75 at week 24 were 66.0% and 34.0%, respectively. Median dermatology life quality index dropped from 15 at baseline to 5 at week 24 (<em>P</em> < .001). Week 4 changes in interleukin-19 serum levels predicted week 24 clinical response.</div></div><div><h3>Conclusion</h3><div>Guselkumab may be a promising therapeutic option for PPP in Caucasian patients.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 69-78"},"PeriodicalIF":0.0,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of the nasal crease with a single phenol croton peel session 用一次苯酚巴豆皮治疗鼻翼皱褶

JAAD International Pub Date : 2024-10-01 DOI: 10.1016/j.jdin.2024.08.020

Gustavo Carneiro Nogueira MD , Raquel Iracema de Freitas Macedo Oliveira MD , Mariana Rocha Andrade , Bárbara Arze Rocha , Marina Vieira Rodrigues de Queiroz MD , Ana Carolina Tardin Rodrigues de Medeiros MD , Gisele Viana de Oliveira MD

引用次数: 0

Resistance to cosmetic botulinum toxin A: A 15-patient case series across 12 sites 美容肉毒杆菌毒素 A 的抗药性：12 个地点的 15 例患者系列病例

JAAD International Pub Date : 2024-09-28 DOI: 10.1016/j.jdin.2024.08.021

Carlos G. Wambier MD, PhD , Fatima N. Mirza MD, MPH , Sarah P.F. Wambier MD, PhD , Vince Bertucci MD , Jean Carruthers MD , Joely Kaufman MD , John Martin MD , J. Barton Sterling MD , Flávia Brasileiro MD , Carolina Marçon MD, MSc , Allison J. Brown MD , Miranda Rosenberg MD , Lilia R.S. Guadanhim MD, PhD , Doris Hexsel MD

引用次数: 0

Incidence of melanoma in situ among racial and ethnic minorities in the United States 美国少数民族原位黑色素瘤发病率

JAAD International Pub Date : 2024-09-27 DOI: 10.1016/j.jdin.2024.08.015

Gurman S. Dhaliwal MD , Adina Greene BA , Andy Ho BS , Aaron R. Mangold MD , Collin M. Costello MD

引用次数: 0

Gastrointestinal comorbidities in patients with acne vulgaris: A population-based retrospective study 寻常型痤疮患者的胃肠道合并症：一项基于人群的回顾性研究

JAAD International Pub Date : 2024-09-27 DOI: 10.1016/j.jdin.2024.08.022

Yu-Wen Chen MD , Chun-Ying Wu MD, PhD , Yi-Ju Chen MD, PhD

{"title":"Gastrointestinal comorbidities in patients with acne vulgaris: A population-based retrospective study","authors":"Yu-Wen Chen MD , Chun-Ying Wu MD, PhD , Yi-Ju Chen MD, PhD","doi":"10.1016/j.jdin.2024.08.022","DOIUrl":"10.1016/j.jdin.2024.08.022","url":null,"abstract":"<div><h3>Background</h3><div>The gut-skin-brain axis has been long postulated in acne vulgaris. Few studies focused on bowel habits in patients with acne vulgaris have yielded controversial results.</div></div><div><h3>Objectives</h3><div>To examine the relationship between acne vulgaris and gastrointestinal comorbidities.</div></div><div><h3>Methods</h3><div>We conducted a nationwide case-control study using data from the Taiwan National Health Insurance Research Database spanning the years 1997 to 2013. Acne vulgaris and the control group were stratified by age, and we examined the association of gastrointestinal comorbidities across different age, sex, and antibiotic use through conditional logistic regression analysis.</div></div><div><h3>Results</h3><div>A total of 185,491 patients with acne vulgaris were identified. The primary demographic for acne vulgaris comprised adolescents, followed by adult-onset groups, with a female predominance observed across all age subgroups. Patients with acne vulgaris exhibited a significantly elevated risk of developing gastrointestinal comorbidities, including peptic ulcers, irritable bowel syndrome, gastroenteritis, gastroesophageal reflux disease, and constipation. This increased risk was particularly notable in patients aged ≥12 years, and those with moderate-to-severe acne.</div></div><div><h3>Limitations</h3><div>Miscoding and misclassification might have occurred.</div></div><div><h3>Conclusions</h3><div>Patients with Acne vulgaris have higher risks of gastrointestinal comorbidities. For patients with moderate-to-severe acne, gastroenterology specialty consultation may be warranted.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 62-68"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0